Dynamics of prescription drug use, diagnoses and health care utilization after community managed SARS-CoV-2 infection

Study type

• Study topic:
  Disease /health condition
• Study type:
  Non-interventional study
• Scope of the study:
  Disease epidemiology

  Drug utilisation

  Healthcare resource utilisation
• Data collection methods:
  Secondary use of data

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Medical condition to be studied:
  SARS-CoV-2 test positive

  SARS-CoV-2 test negative

Population studied

• Short description of the study population:
  Any individual with a positive or negative reverse-transcriptase polymerase chain reaction (RTPCR) test for SARS-CoV-2 in Denmark during the period 27-02-2020 to 31-05-2020 was eligible for inclusion in the study.
• Age groups:
  Preterm newborn infants (0 – 27 days)

  Term newborn infants (0 – 27 days)

  Infants and toddlers (28 days – 23 months)

  Children (2 to < 12 years)

  Adolescents (12 to < 18 years)

  Adults (18 to < 46 years)

  Adults (46 to < 65 years)

  Adults (65 to < 75 years)

  Adults (75 to < 85 years)

  Adults (85 years and over)
• Estimated number of subjects:
  531619

Study design details

• Main study objective:
  The aim of the study is to examine drug use, hospital diagnoses and health care utilization after SARS-CoV-2 infection.
• Outcomes:
  Primary outcomes are the initiation of prescription drugs or hospital diagnoses that may represent delayed complication or persisting symptoms to SARS-CoV-2 infection and healthcare utilization after SARS-CoV-2 infection. For a detailed list of all outcomes, please see the study protocol
• Data analysis plan:
  The measure of occurrence for initiation of new medication, reinitiation of medication, first-ever diagnoses and readmissions will be the cumulative incidence proportion (IP) during follow up (duration: 90 days). IP differences comparing individuals with community managed SARS-CoV-2 infection to SARS-CoV-2 negative individuals and individuals hospitalized for SARS-CoV-2 infection, will be estimated using generalized linear models using a binomial distribution and an identity link. The rates of healthcare utilization (number of visits per 1000 individuals during follow up) will be quantified during the prior comparator period and follow up (duration: 90 days each) for each cohort. Rate ratios, rate differences and exact 95% confidence intervals comparing the prior comparator period to follow up will be calculated for each cohort.

Documents

Study publications

Lund LC, Hallas J, Nielsen H, et al. Post-acute effects of SARS-CoV-2 infection…